COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Heart Transplant Patients
OSE Immunotherapeutics welcomes FDA Orphan Drug Designation granted to Pegrizeprument (VEL-101) for prevention of organ rejection in heart transplant patients, a novel immunomodulatory treatment developed in partnership with Veloxis Pharmaceuticals -
-
COMMUNIQUÉ DE PRESSE
FORVIA: CHANGES TO THE COMPOSITION OF THE BOARD OF DIRECTORS OF FORVIA SUBJECT TO APPROVAL BY THE 2026 ANNUAL GENERAL MEETING
FORVIA announces changes in Board of Directors composition with Pierre-André de Chalendar appointment and resignation of Michel de Rosen. Details on the 2026 Annual General Meeting -
-
COMMUNIQUÉ DE PRESSE
FORVIA : CHANGEMENTS DANS LA COMPOSITION DU CONSEIL D'ADMINISTRATION DE FORVIA SOUMIS A L'APPROBATION DE SON ASSEMBLEE GENERALE ANNUELLE 2026
Réorganisation du Conseil d'administration de FORVIA avec la nomination de Pierre-André de Chalendar en remplacement de Michel de Rosen. FORVIA, société internationale de technologie automobile, annonce des changements clés -
COMMUNIQUÉ DE PRESSE
Exosens delivers strong Q1 2026 performance, with accelerating defense momentum in digital imaging and night vision; Fully on track to deliver on 2026 guidance
Exosens reports strong Q1 2026 performance with accelerating defense momentum in digital imaging and night vision. On track to deliver on 2026 guidance -
-
COMMUNIQUÉ DE PRESSE
Leclanché SA renforce sa structure de capital par conversion de dette en fonds propres
Leclanché SA renforce sa structure de capital par conversion de dette en fonds propres. Annonce événementielle au sens de l'art. 53 RC (SIX) - YVERDON-LES-BAINS, Suisse - Leclanché, fournisseur mondial de solutions de stockage d'énergie, convertit CHF 10,0 millions de dette en capitaux propres -
